Report: Tuesday, July 28, 2026, at 7:00 a.m. ET
Conference call: 8:00 a.m. ET (investor.incyte.com)
Incyte enters the quarter with strong commercial momentum, several pipeline wins and a share price roughly 24% above its April 27 close. The setup is favorable, but expectations have risen.
This will also be an unusually complicated quarter to interpret. Incyte expects to record a $246 million one-time, non-cash benefit from resolving its Opzelura Medicaid-rebate dispute with CMS. That benefit, along with a lasting improvement in Opzelura gross-to-net deductions, could make reported revenue and earnings look substantially stronger than the underlying business. Management has said it will update 2026 guidance for the settlement. (sec.gov)
The most important questions are therefore:
Published estimates vary, partly because of the unusual Opzelura accounting item. One commonly cited set of estimates is:
| Metric | Q2 expectation |
|---|---|
| Revenue | ~$1.40 billion |
| Adjusted EPS | ~$1.85 |
| Jakafi sales | ~$796.5 million |
| Opzelura sales | ~$214.7 million |
Zacks’ estimates imply approximately 4% year-over-year growth for Jakafi and 31% for Opzelura. Other data providers show materially higher consolidated estimates, reinforcing the need to examine the company’s reconciliation rather than judging the quarter against a single headline consensus. (zacks.com)
In Q1, Incyte reported $1.27 billion of revenue, $1.10 billion of product sales and $1.81 of non-GAAP diluted EPS. Product sales increased 20% year over year, while management reaffirmed all 2026 guidance ranges. (investor.incyte.com)
Opzelura generated $143 million in Q1, up 20% year over year, despite normal seasonal weakness. Management said underlying U.S. prescription demand grew 17%, while international sales increased 56% to $37 million.
The Q2 comparison is against $164 million in Q2 2025, and the cited consensus of approximately $215 million would represent about 31% growth. In addition to normal seasonal improvement, investors should watch:
On June 25, the EMA’s CHMP issued a positive opinion recommending Opzelura for adults with moderate atopic dermatitis when standard topical therapies are inadequate or inappropriate. An eventual European Commission approval would open an additional growth market; management previously estimated that European moderate AD could eventually add $200–300 million in annual sales. (ema.europa.eu)
Incyte plans to reverse approximately $246 million of previously recorded Opzelura rebate accruals. It will also stop accruing for the disputed line-extension treatment going forward.
Investors should separate three items:
A large reported beat that comes primarily from item two would be less meaningful than an increase in the recurring sales outlook.
Jakafi produced $758 million in Q1, up 7% as paid demand increased 6%. The full-year guide remains $3.22–3.27 billion, while Q2 consensus is approximately $796.5 million. (zacks.com)
Points to watch include:
The FDA approved once-daily Jakafi XR on May 1, and the product became available for pharmacy orders on May 8. Management previously estimated that XR could represent 10%–30% of the Jakafi franchise by 2029, making the launch strategically important even if Q2 revenue is modest. (investor.incyte.com)
A successful XR conversion could improve patient convenience and help support franchise durability. Conversely, investors will want assurance that conversions do not produce near-term reimbursement friction or cannibalization-related disruption.
In Q1, the hematology and oncology portfolio generated $204 million, up 116% year over year:
| Product | Q1 2026 sales |
|---|---|
| Niktimvo | $55 million |
| Monjuvi/Minjuvi | $49 million |
| Zynyz | $41 million |
| Iclusig | $35 million |
| Pemazyre | $23 million |
The portfolio’s full-year guidance is $800–880 million. Q1 was already running around the midpoint of the quarterly pace needed to reach that range, making another quarter near or above $200 million important.
Niktimvo is the most important current launch in this group. In Q1, management said it had captured approximately 32% of the third-line-or-later chronic-GVHD market, with broad adoption across U.S. transplant centers.
Investors should look for:
The Phase 3 frontMIND trial strengthened the first-line DLBCL opportunity. Adding tafasitamab and lenalidomide to R-CHOP reduced the risk of progression or death by 25%, with a progression-free survival hazard ratio of 0.75. (investor.incyte.com)
The main call questions are:
Monjuvi’s existing follicular-lymphoma launch should continue to support near-term sales, but the first-line DLBCL indication represents the larger potential value driver.
Zynyz posted $41 million in Q1 following rapid adoption in first-line squamous-cell anal carcinoma. Investors should assess whether this early ramp is sustainable or included any launch-related stocking effects.
Current 2026 guidance is:
| Metric | Current guidance |
|---|---|
| Total product sales | $4.77–4.94 billion |
| Jakafi | $3.22–3.27 billion |
| Opzelura | $750–790 million |
| Hematology and oncology portfolio | $800–880 million |
| GAAP R&D + SG&A | $3.495–3.675 billion |
| Non-GAAP R&D + SG&A | $3.205–3.375 billion |
Management has explicitly said it will update guidance for the CMS resolution. Consequently, some increase is already expected and should not automatically be considered a positive surprise.
A high-quality raise would include:
A low-quality raise would primarily add the one-time CMS benefit while leaving underlying demand assumptions unchanged—or would be offset by meaningfully higher R&D and launch spending.
June’s EHA data reinforced INCA033989 as one of Incyte’s most valuable internal pipeline assets.
In essential thrombocythemia, 87% of patients achieved a complete or partial hematologic response and 70% achieved a complete response. In myelofibrosis, week-24 SVR35 was 27% with monotherapy and 30% in combination with ruxolitinib; molecular responses supported the potential for disease modification. (investor.incyte.com)
Key earnings-call questions:
The market is increasingly assigning value to this program, so delays or a less favorable regulatory path could matter even if quarterly earnings beat expectations.
The FDA has accepted the NDA for moderate-to-severe hidradenitis suppurativa, with Incyte targeting a potential U.S. approval in Q1 2027. Positive Phase 3 vitiligo results support regulatory applications planned for the first half of 2027. (sec.gov)
Investors should listen for:
The call should also update:
The principal question is whether all second-half clinical readouts and trial initiations remain on schedule.
Incyte completed its acquisition of Vega Therapeutics on July 6 for $1.25 billion upfront, with up to $750 million of additional sales milestones. The acquisition adds latarcibart, formerly VGA039, a once-monthly subcutaneous antibody in Phase 3 development for von Willebrand disease. The upfront payment will be recorded as a one-time R&D expense in Q3 in both GAAP and non-GAAP results. (investor.incyte.com)
Shortly after closing, Incyte reported that latarcibart produced an 81% median reduction in annualized bleeding rate in a 16-patient Phase 1/2 multidose study. The pivotal VIVID-6 trial is enrolling. (investor.incyte.com)
Management should clarify:
Incyte ended Q1 with approximately $4.0 billion in cash and marketable securities. The transaction is affordable, but investors will expect evidence that the asset’s opportunity justifies a sizable upfront payment based on an early, small clinical dataset.
The quarter’s headline revenue and EPS may be misleading because of the $246 million Opzelura accounting benefit. The cleanest signals will be:
Incyte’s investment case is increasingly shifting from “Jakafi plus pipeline” to a broader commercial and late-stage portfolio. Q2 needs to show that this diversification is translating into durable revenue growth—not simply a favorable accounting quarter.